# Oncotherapeutics clinical trials: 22 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 22 trials with Oncotherapeutics as lead sponsor, 4 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Oncotherapeutics: 22 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/company/oncotherapeutics

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 22
- Recruiting or not yet: 4
- Read on: November 19, 2026

## Trials

The 22 newest of 22, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| January 25, 2024 | NCT06225310 | A Trial of Selinexor, Ruxolitinib and Methylprednisolone | Oncotherapeutics | Phase 1 | Recruiting | Multiple Myeloma in Relapse, Multiple Myeloma, Refractory | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06225310) |
| January 17, 2024 | NCT06209606 | Pilot Study Using Changes in Serum BCMA to Determine Disease Progression in Multiple Myeloma | Oncotherapeutics | Early phase 1 | Recruiting | Multiple Myeloma | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06209606) |
| November 2, 2023 | NCT06115135 | A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma | Oncotherapeutics | Phase 2 | Recruiting | Multiple Myeloma in Relapse, Multiple Myeloma, Refractory | 39 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06115135) |
| August 19, 2020 | NCT04519476 | Selinexor Treatment for Multiple Myeloma Patients Who Are Refractory to Lenalidomide-containing Therapy. | Oncotherapeutics | Phase 1 | Unknown | Refractory Multiple Myeloma | 22 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04519476) |
| November 7, 2018 | NCT03733691 | Ph 2 Maintenance Trial: Ixazomib vs Ixazomib-Lenalidomide for MM Patients | Oncotherapeutics | Phase 2 | Terminated | Newly Diagnosed Multiple Myeloma | 19 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03733691) |
| April 12, 2017 | NCT03110822 | A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients | Oncotherapeutics | Phase 1 | Recruiting | Multiple Myeloma | 134 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03110822) |
| April 7, 2017 | NCT03104270 | Combination Study for High Risk Multiple Myeloma Patients | Oncotherapeutics | Phase 2 | Terminated | Multiple Myeloma | 13 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03104270) |
| November 19, 2014 | NCT02294357 | Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib | Oncotherapeutics | Phase 2 | Terminated | Multiple Myeloma | 45 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02294357) |
| August 1, 2014 | NCT02206425 | Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients | Oncotherapeutics | Phase 1/2 | Completed | Multiple Myeloma | 45 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02206425) |
| July 11, 2014 | NCT02188368 | Pomalidomide for Lenalidomide for Relapsed or Refractory Multiple Myeloma Patients | Oncotherapeutics | Phase 2 | Terminated | Multiple Myeloma | 45 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02188368) |
| February 15, 2013 | NCT01792102 | Safety, Efficacy, and Pharmacodynamics of a 60-Minute Infusion of Carfilzomib for Progressive Multiple Myeloma | Oncotherapeutics | Phase 1/2 | Unknown | Multiple Myeloma | 38 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01792102) |
| October 2, 2012 | NCT01697839 | Serum Vitamin D Levels and Peripheral Neuropathy Among Multiple Myeloma Patients | Oncotherapeutics | Observational | Completed | Multiple Myeloma, Peripheral Neuropathy | 110 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01697839) |
| September 27, 2012 | NCT01695330 | Subcutaneous (SC) Bortezomib-Regimens for Patients With RR MM Failing Prior IV Bortezomib-Containing Regimens | Oncotherapeutics | Phase 2 | Terminated | Multiple Myeloma | 5 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01695330) |
| February 29, 2012 | NCT01541332 | Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Relapsed/Refractory Multiple Myeloma | Oncotherapeutics | Phase 1/2 | Unknown | Multiple Myeloma | 70 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01541332) |
| June 3, 2011 | NCT01365559 | Study of Carfilzomib for Multiple Myeloma Patients Who Are Relapsed/Refractory to Bortezomib-containing Treatments | Oncotherapeutics | Phase 1/2 | Completed | Multiple Myeloma | 39 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01365559) |
| July 12, 2010 | NCT01160484 | Pegylated Liposomal Doxorubicin, Bortezomib, Dexamethasone and Lenalidomide for Relapsed/Refractory Multiple Myeloma | Oncotherapeutics | Phase 2 | Completed | Multiple Myeloma | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01160484) |
| July 12, 2010 | NCT01160380 | A Study of the Effectiveness of Armodafinil to Treat Cancer-Related Fatigue in Patients With Multiple Myeloma | Oncotherapeutics | Phase 3 | Completed | Fatigue, Multiple Myeloma | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01160380) |
| August 28, 2008 | NCT00743288 | Melphalan and Panobinostat (LBH589) for the Treatment of Patients With Recurrent Multiple Myeloma | Oncotherapeutics | Phase 1/2 | Completed | Multiple Myeloma | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00743288) |
| August 27, 2008 | NCT00742404 | Doxorubicin Hydrochloride Liposome, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma | Oncotherapeutics | Phase 2 | Unknown | Multiple Myeloma and Plasma Cell Neoplasm | 35 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00742404) |
| April 25, 2006 | NCT00317811 | Bortezomib, Ascorbic Acid, and Melphalan in Treating Patients With Newly Diagnosed Multiple Myeloma | Oncotherapeutics | Phase 2 | Completed | Multiple Myeloma and Plasma Cell Neoplasm | 35 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00317811) |
| April 21, 2006 | NCT00316940 | Samarium 153 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma | Oncotherapeutics | Phase 1 | Completed | Multiple Myeloma and Plasma Cell Neoplasm | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00316940) |
| June 11, 2004 | NCT00085345 | Melphalan, Arsenic Trioxide, and Ascorbic Acid in Treating Patients With Relapsed or Refractory Multiple Myeloma | Oncotherapeutics | Phase 2 | Withdrawn | Stage II Multiple Myeloma, Stage III Multiple Myeloma, Refractory Plasma Cell Neoplasm | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00085345) |

## By phase

| Phase | Trials |
| --- | --- |
| Early phase 1 | 1 |
| Phase 1 | 4 |
| Phase 1/2 | 5 |
| Phase 2 | 10 |
| Phase 3 | 1 |
| Observational | 1 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 8 |
| Terminated | 5 |
| Unknown | 4 |
| Recruiting | 4 |
| Withdrawn | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Multiple Myeloma | 22 |
| Recurrence | 5 |
| Neoplasms, Plasma Cell | 4 |
| Fatigue | 1 |
| Neoplasms | 1 |
| Peripheral Nervous System Diseases | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Wine bars in the United States](https://specstream.ai/data/businesses/wine-bars/united-states)
- [Pediatric surgery practices in the United States](https://specstream.ai/data/businesses/pediatric-surgery-practices/united-states)
- [Furniture wholesalers in the United States](https://specstream.ai/data/businesses/furniture-wholesalers/united-states)
- [Barbecue restaurants in the United States](https://specstream.ai/data/businesses/barbecue-restaurants/united-states)
- [Shipping and delivery companies in the United States](https://specstream.ai/data/businesses/shipping-and-delivery-companies/united-states)
- [Jewelry and watches manufacturers in the United States](https://specstream.ai/data/businesses/jewelry-and-watches-manufacturers/united-states)
